Breast cancer

June 9, 2021

Esmo Breast Cancer 2021: analysis of two important studies presented during the congress

Clinical Oncologist at Grupo Oncoclínicas discusses phase II DESTINY-Breast01 study and meta-analysis that included four randomized clinical trials involving patients with triple-negative breast cancer    The ESMO Breast Cancer 2021 event, held […]
May 24, 2021

Association of RAD51 with homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC): Analysis of the GeparSixto trial

Currently available genetic tests analyzing homologous recombination deficiency (HRD) have limited predictive value    During the ESMO Breast Cancer 2021 Congress, in virtual format, a retrospective […]
May 21, 2021

Immunomodulatory effect of denosumab in early breast cancer

Most breast cancers exhibit low T–lymphocyte infiltration and do not respond satisfactorily to immune correceptor inhibitors, leading to the need for new therapeutic strategies that act on anti-tumor immune […]
May 20, 2021

Meta-analysis assesses the efficacy of adding immunotherapy to neoadjuvant chemotherapy in triple-negative breast cancer

Presented during ESMO Breast Cancer 2021, meta-analysis approaches immune checkpoint inhibitors (ICIs), which have shown promising antitumor activities in several malignancies   ESMO Breast Cancer 2021 starts today in virtual format, a […]
April 19, 2021

Selective androgen receptor degraders may provide a future therapeutic option for women with LAR subtype triple-negative breast cancer

Triple-negative breast cancer is an aggressive tumor with lower overall survival compared to other types of breast malignancies. Of the 6 molecularly classified TNBC subtypes, about 10 to […]
March 31, 2021

Molecular signature panel for DCIS predicts risk of local recurrence and benefit of radiotherapy after breast conservative surgery.

Radiotherapy after breast-conserving surgery for the treatment of ductal carcinoma in situ (DCIS) reduces the risk of ipsilateral breast events without changing survival   Between March 18th and 19th, SSO 2021 (International Conference […]
July 15, 2020

Combination of abemaciclib and adjuvant hormone therapy increases invasive disease-free survival in high-risk early breast cancer RH + HER2-

New therapeutic option for patients with high-risk HR-positive, HER2-negative breast cancer Abemaciclib in combination with standard adjuvant endocrine therapy (ET) achieved its primary objective in the […]
May 14, 2020

FDA approves Tucatinib in combination with trastuzumab plus capecitabine for HER2-positive advanced breast cancer

Approval is based on exclusive clinical trial that included patients with active brain metastases On April 17, 2020, the U.S. FDA (US Food and Drug Administration) […]
May 13, 2020

FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple-negative breast cancer

Fast Track is based on the response rate and duration of the response and reinforces the premise that the Trop-2 antigen is an important target to […]